EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Oncology drug expenditure governance in an antineoplastic drug unit: comparative economic analysis 2023–2025 and the stratified recovery rate

Filomena D'Amico, Francesco Colasuonno, Loredana Brandi, Viviana Bruno, Alessandro Maggi, Antonio Ungaro, Tiziana Guarino, Salvatore Pisconti, Vito Gregorio Colacicco

Global and Regional Health Technology Assessment · 17.11.2026 · 13 (1) · 309-312

DOI: 10.33393/grhta.2026.3970 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Global and Regional Health Technology Assessment, online erschienen am 17.11.2026. Verfasst von Filomena D'Amico und 8 weiteren Autor:innen. Die Arbeit nennt 7 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Direct hospital pharmaceutical expenditure in Italy grew by +6.0% in 2025. Antineoplastic Drug Units (ADUs) play a key governance role through AIFA registry management, managed entry agreement (MEA) recovery, and prescribing appropriateness monitoring. No standardized indicator distinguishes recoveries dependent on local activity from those determined nationally.

Methods

Retrospective three-year comparative economic analysis, 2023-2025, at the ADU of a local health authority in southern Italy (~540,000 inhabitants). Expenditure, patient volumes, preparation counts, and recoveries were extracted from the AIFA registry platform and ADU management system. Recoveries were stratified into Tier 1 (national: AIFA MEA rebates, Innovative Drug Fund receipts) and Tier 2 (local: Law 648/96 recoveries, trial and compassionate use cost avoidance). Gross (all recoveries over net expenditure) and Local (Tier 2 over net expenditure) Recovery Rates were calculated.

Results

Net expenditure grew +8.0% in 2023, +19.0% in 2024 and +3.86% in 2025, below the +6.0% national growth, despite a +19.2% increase in treated patients (3,341 vs 2,804) and +21.8% in preparations. Cost per patient decreased from €11,286 to €9,837 (−12.8%). Total recoveries were €5,261,136, €5,291,062, and €8,918,159. The Gross Recovery Rate was 19.8%, 16.7%, and 27.1%; the Local Recovery Rate was 6.7%, 4.7%, and 6.5%.

Conclusions

The ADU governance model was associated with simultaneous expansion of patient access and reduction of per-patient cost. The stratified Recovery Rate separates recoveries dependent on local activity from those determined nationally, offering a transparent, reproducible indicator for benchmarking ADU governance across Italian NHS settings and European health systems with national MEA frameworks.

Zitieren

APA

D'Amico, F., Colasuonno, F., Brandi, L., Bruno, V., Maggi, A., Ungaro, A., Guarino, T., Pisconti, S., & Colacicco, V. G. (2026). Oncology drug expenditure governance in an antineoplastic drug unit: comparative economic analysis 2023–2025 and the stratified recovery rate. Global and Regional Health Technology Assessment, 13(1), 309-312. https://doi.org/10.33393/grhta.2026.3970

Vancouver

D'Amico F, Colasuonno F, Brandi L, Bruno V, Maggi A, Ungaro A, et al. Oncology drug expenditure governance in an antineoplastic drug unit: comparative economic analysis 2023–2025 and the stratified recovery rate. Global and Regional Health Technology Assessment. 2026;13(1):309-312. doi:10.33393/grhta.2026.3970

BibTeX
@article{DAmico2026,
  author = {D'Amico, Filomena and Colasuonno, Francesco and Brandi, Loredana and Bruno, Viviana and Maggi, Alessandro and Ungaro, Antonio and Guarino, Tiziana and Pisconti, Salvatore and Colacicco, Vito Gregorio},
  title = {Oncology drug expenditure governance in an antineoplastic drug unit: comparative economic analysis 2023–2025 and the stratified recovery rate},
  journal = {Global and Regional Health Technology Assessment},
  year = {2026},
  volume = {13},
  number = {1},
  pages = {309--312},
  doi = {10.33393/grhta.2026.3970}
}
Kostenlos starten →